I am not in ER but I would like to get any insight from people who are. What are your thoughts on the potential consequences of the directive? What will it mean for the ER industry and EU capital markets? Are your teams talking about it at all? Is it going to reshape/restructure how the sell-side is structured in the EU?
↧